With decades of investment in cutting-edge science and innovation—equating to 12.4% of our sales in 2023—we are committed to furthering our capabilities into the future. Our collaborative mindset allows us to work closely with leading experts around the globe to innovate and develop novel technologies such as AI-based drug discovery, immunology, biological treatments, and mRNA, amongst others. From drug discovery to product development and commercialization, our holistic approach ensures the delivery of groundbreaking treatments through in-house efforts, external partnerships, and strategic licensing agreements. We firmly believe that innovation is the cornerstone of our success, permeating not just our R&D efforts but also influencing novel approaches and technologies across our entire organizational ecosystem. This includes manufacturing, insight generation, communication, and operational structures. Our R&D Centre Nestled in the vibrant biomedical science and healthcare innovation hub of Barcelona, our pharmaceutical R&D centre is exclusively dedicated to medical dermatology. Here, our team of leading scientists and innovation experts are advancing knowledge in skin science and identifying new dermatological treatment options across a range of technologies. During 2023, ZeClinics and Centrient joined Almirall's R&D facilities, creating a collaborative environment for our scientists and contributing to our ambition of becoming a scientific leader in medical dermatology. Our focus on innovation Ana Blanco, Senior Scientist, In Vivo Pharmacology.